Rockefeller Capital Management L.P. decreased its stake in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 5.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 146,794 shares of the financial services provider’s stock after selling 8,860 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.29% of iShares Biotechnology ETF worth $21,369,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Williams Financial LLC purchased a new stake in iShares Biotechnology ETF in the 2nd quarter valued at approximately $867,000. PVG Asset Management Corp acquired a new position in iShares Biotechnology ETF during the second quarter worth approximately $415,000. Huntington National Bank raised its stake in iShares Biotechnology ETF by 17.9% during the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after purchasing an additional 160 shares during the period. Concourse Financial Group Securities Inc. increased its holdings in shares of iShares Biotechnology ETF by 22.4% during the 2nd quarter. Concourse Financial Group Securities Inc. now owns 656 shares of the financial services provider’s stock worth $90,000 after buying an additional 120 shares during the last quarter. Finally, Raymond James & Associates grew its position in iShares Biotechnology ETF by 4.4% during the second quarter. Raymond James & Associates now owns 189,766 shares of the financial services provider’s stock valued at $26,047,000 after acquiring an additional 7,931 shares during the period. 62.45% of the stock is currently owned by institutional investors and hedge funds.
iShares Biotechnology ETF Price Performance
IBB opened at $141.55 on Monday. iShares Biotechnology ETF has a 1 year low of $119.95 and a 1 year high of $150.57. The firm has a 50 day moving average price of $142.71 and a 200 day moving average price of $142.06.
iShares Biotechnology ETF Announces Dividend
iShares Biotechnology ETF Company Profile
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- Learn Technical Analysis Skills to Master the Stock Market
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- What is a support level?
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Trading Halts Explained
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.